Breakthrough Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae during Combination Therapy with Colistin and Tigecycline

Samankaltaisia teoksia

• Characteristics and Clinical Outcomes of Extended-Spectrum beta-lactamase-producing Klebsiella pneumoniae Bacteremia in Cancer Patients
  Tekijä: Nham, Eliel, et al.
  Julkaistu: (2020)
• Reply to “Breakthrough Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae during Combination Therapy with Colistin and Tigecycline”
  Tekijä: Albur, Mahableshwar, et al.
  Julkaistu: (2012)
• Native valve endocarditis due to extended spectrum β-lactamase producing Klebsiella pneumoniae
  Tekijä: Jung, Hyun-Ae, et al.
  Julkaistu: (2014)
• Epidemiology of Ciprofloxacin Resistance and Its Relationship to Extended-Spectrum β-Lactamase Production in Proteus mirabilis Bacteremia
  Tekijä: Sohn, Kyung Mok, et al.
  Julkaistu: (2011)
• Emergence of serotype K1 Klebsiella pneumoniae ST23 strains co-producing the plasmid-mediated AmpC beta-lactamase DHA-1 and an extended-spectrum beta-lactamase in Korea
  Tekijä: Cheong, Hae Suk, et al.
  Julkaistu: (2016)